Evogene Ltd.
Every calculator, already run for EVGN
Open the full toolkit →You have the numbers on EVGN. Get the argument.
A written report on which of these readings actually decide the outcome for Evogene Ltd., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
1 analysts covering EVGNOwnership & short interest
About Evogene Ltd.
Evogene Ltd., together with its subsidiaries, operates as a computational biology company in Israel, the United States, Europe, and Africa. It operates through three segments: Agriculture, Human Health, and Industrial Applications. The company engages in the agricultural activities, including seed traits and ag-chemicals activities; and design novel small molecules for drug development by utilizing ChemPass AI, a computational generative AI engine. It also focuses on the development and commercialization of castor bean seeds for industrial uses. In addition, the company medical cannabis products. It has a collaboration with LMU University Hospital Munich to develop novel therapies for hyper-…
EVGN — frequently asked
Is EVGN a buy right now?
Wall Street's consensus rating on Evogene Ltd. is none across 1 analysts, with a mean price target of $2.15 (+257% vs. the current $0.60). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
When is EVGN's next earnings date?
Evogene Ltd. is next scheduled to report earnings around Aug 18, 2026. A full EVGN research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
Compare Evogene Ltd. against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Evogene Ltd.
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full EVGN research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Evogene Ltd., in minutes. 3 free reports included with every account — no credit card required.